EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Pharmaceutical Industry in 2025: An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G de la Torre iD, Fernando Albericio iD

Molecules · 26.01.2026 · 31 (3) · 419

DOI: 10.3390/molecules31030419 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 26.01.2026. Verfasst von Beatriz G de la Torre und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. Hauptthemen laut MEDLINE: Drug Approval, Drug Industry. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of KwaZulu-Natal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2025, the U.S. Food and Drug Administration (FDA) approved 44 new drugs, reflecting a slight decrease compared to previous years but maintaining the overall trends in pharmaceutical innovation. Biologics accounted for 25% of approvals, including nine monoclonal antibodies (mAbs), two antibody–drug conjugates (ADCs), and one fusion protein, with cancer remaining the primary therapeutic focus. TIDES, comprising three oligonucleotides and one peptide, continued to consolidate their presence in the market, with the three oligonucleotides featuring N-acetylgalactosamine (GalNAc) for liver-targeted delivery. Small molecules dominate the remainder, with a high prevalence of N-aromatic moieties and fluorine atoms present in most of the molecules. Peptide manufacturing and sustainability concerns, including PFAS usage, remain key challenges. Despite these advances, the high cost of innovative therapies limits access, particularly in low- and middle-income countries. This report provides a structural and chemical analysis of the newly approved drugs, highlighting trends in molecular design, therapeutic areas, and technological innovations shaping modern drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalDrug IndustryUnited StatesUnited States Food and Drug AdministrationHumansAntibodies, MonoclonalImmunoconjugatesDrug Discovery

Stichwörter der Autor:innen

ADCPFASTIDESantibodiesantibody drug conjugatearomatic-based drugsbiologicschemical entitiesfluorine-based drugsnatural productsnew chemical entitiesoligonucleotidespeptidespolyfluoroalkyl substances

Substanzen

Antibodies, MonoclonalImmunoconjugates

Autor:innen und Institutionen

  • School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
  • School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
  • Department of Inorganic and Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.

ORCID-Profile: Beatriz G de la Torre, Fernando Albericio

Förderung

  • University of KwaZulu-Natal

Zitieren

APA

de la Torre, B. G., & Albericio, F. (2026). The Pharmaceutical Industry in 2025: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 31(3), 419. https://doi.org/10.3390/molecules31030419

Vancouver

de la Torre BG, Albericio F. The Pharmaceutical Industry in 2025: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2026;31(3):419. doi:10.3390/molecules31030419

BibTeX
@article{delaTorre2026,
  author = {de la Torre, Beatriz G and Albericio, Fernando},
  title = {The Pharmaceutical Industry in 2025: An Analysis of FDA Drug Approvals from the Perspective of Molecules},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {3},
  pages = {419},
  doi = {10.3390/molecules31030419}
}
Kostenlos starten →